[go: up one dir, main page]

SA520420930B1 - تركيبات مولدة للمناعة مشتملة على مولدات مضاد ساكاريد كبسولية متقارنة واستخداماتها - Google Patents

تركيبات مولدة للمناعة مشتملة على مولدات مضاد ساكاريد كبسولية متقارنة واستخداماتها

Info

Publication number
SA520420930B1
SA520420930B1 SA520420930A SA520420930A SA520420930B1 SA 520420930 B1 SA520420930 B1 SA 520420930B1 SA 520420930 A SA520420930 A SA 520420930A SA 520420930 A SA520420930 A SA 520420930A SA 520420930 B1 SA520420930 B1 SA 520420930B1
Authority
SA
Saudi Arabia
Prior art keywords
immunogenic compositions
capsular saccharide
saccharide antigens
compositions containing
containing capsular
Prior art date
Application number
SA520420930A
Other languages
English (en)
Inventor
كريشنا براساد أفاري
أنتوني إميني إميليو
جو جيانكسين
كيم جين-هوان
كوبر ديفيد
كومار كاينتان راجيش
أوت يانسن كاترين
ويليام برايد مايكل
هان مينجمينج
جو واتسن ويندي
يانج يو-يينج
Original Assignee
فايزر إنك.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52630420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA520420930(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by فايزر إنك. filed Critical فايزر إنك.
Publication of SA520420930B1 publication Critical patent/SA520420930B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبات مولدة للمناعة (immunogenic compositions) جديدة تشمل مولدات مضاد saccharide كبسولية متقارنة (conjugated capsular saccharide antigens) (متقارنات سكر (glycoconjugates)) واستخداماتها. تشمل نموذجيا التركيبات المولدة للمناعة (immunogenic compositions) من الاختراع الحالي متقارن سكر (glycoconjugate) واحد على الأقل من النوع المصلي S. pneumoniae غير الموجود في Prevnar، Synflorix و/أو Prevnar 13. يتعلق الاختراع أيضا بتلقيح كائنات آدمية، تحديدا الرضع وكبار السن، ضد الإصابات بعدوى المكورات الرئوية (pneumoccocal) باستخدام التركيبات المولدة للمناعة (immunogenic compositions) الجديدة المذكورة. شكل 1
SA520420930A 2014-01-21 2016-07-19 تركيبات مولدة للمناعة مشتملة على مولدات مضاد ساكاريد كبسولية متقارنة واستخداماتها SA520420930B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461929547P 2014-01-21 2014-01-21

Publications (1)

Publication Number Publication Date
SA520420930B1 true SA520420930B1 (ar) 2024-01-09

Family

ID=52630420

Family Applications (2)

Application Number Title Priority Date Filing Date
SA520420930A SA520420930B1 (ar) 2014-01-21 2016-07-19 تركيبات مولدة للمناعة مشتملة على مولدات مضاد ساكاريد كبسولية متقارنة واستخداماتها
SA516371506A SA516371506B1 (ar) 2014-01-21 2016-07-19 تركيبات مولدة للمناعة مشتملة على مولدات مضاد ساكاريد كبسولية متقارنة واستخداماتها

Family Applications After (1)

Application Number Title Priority Date Filing Date
SA516371506A SA516371506B1 (ar) 2014-01-21 2016-07-19 تركيبات مولدة للمناعة مشتملة على مولدات مضاد ساكاريد كبسولية متقارنة واستخداماتها

Country Status (28)

Country Link
US (1) US9492559B2 (ar)
EP (3) EP3607966A1 (ar)
JP (6) JP6335326B2 (ar)
KR (5) KR20200108496A (ar)
CN (6) CN106102770B (ar)
AR (3) AR099445A1 (ar)
AU (6) AU2015208821B2 (ar)
CA (3) CA3206112A1 (ar)
DK (1) DK3096785T3 (ar)
ES (1) ES2820824T3 (ar)
FR (2) FR22C1028I2 (ar)
HU (3) HUE051728T2 (ar)
IL (6) IL296681B2 (ar)
LU (2) LUC00268I2 (ar)
MX (4) MX379051B (ar)
NO (2) NO2022021I1 (ar)
NZ (5) NZ755770A (ar)
PE (2) PE20212335A1 (ar)
PH (2) PH12016501243B1 (ar)
PL (1) PL3096785T3 (ar)
PT (1) PT3096785T (ar)
RU (1) RU2771293C2 (ar)
SA (2) SA520420930B1 (ar)
SG (2) SG11201604728XA (ar)
SI (1) SI3096785T1 (ar)
TW (4) TWI748810B (ar)
WO (1) WO2015110941A2 (ar)
ZA (1) ZA201603925B (ar)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
CN104815327A (zh) 2005-04-08 2015-08-05 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
PT2885007T (pt) 2012-08-16 2018-12-10 Pfizer Processos e composições de glicoconjugação
BR112016015835B1 (pt) * 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
EP3607966A1 (en) 2014-01-21 2020-02-12 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
HRP20211288T1 (hr) * 2014-01-21 2021-11-26 Pfizer Inc. Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
FI3244917T3 (fi) * 2015-01-15 2023-05-25 Pfizer Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi
MX394142B (es) * 2015-04-28 2025-03-24 Biological E Ltd Método para la separación de proteína y otras impurezas de polisacáridos capsulares microbianos.
KR102045663B1 (ko) * 2015-05-04 2019-11-15 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
KR102225282B1 (ko) * 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN106110316A (zh) * 2016-06-27 2016-11-16 北京智飞绿竹生物制药有限公司 一种肺炎球菌结合物组合疫苗的制备方法
EP3493837B1 (en) * 2016-08-05 2022-08-31 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3031797A1 (en) * 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
JP2018042864A (ja) * 2016-09-15 2018-03-22 株式会社三洋物産 遊技機
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
CN108144052A (zh) * 2016-12-02 2018-06-12 武汉博沃生物科技有限公司 肺炎链球菌多糖-蛋白质缀合物及其制取方法和用途
ES3024474T3 (en) * 2016-12-30 2025-06-04 Vaxcyte Inc Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
SI3570879T1 (sl) 2017-01-20 2022-06-30 Pfizer Inc. Imunogenska kompozicija za uporabo v pnevmokoknih cepivih
KR102650073B1 (ko) * 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
KR20190108583A (ko) 2017-01-31 2019-09-24 머크 샤프 앤드 돔 코포레이션 다당류-단백질 접합체 제조 방법
US11246918B2 (en) 2017-02-03 2022-02-15 Eva Barbara Schadeck Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
PT3585803T (pt) * 2017-02-24 2025-12-22 Merck Sharp & Dohme Formulações de vacina pneumocócica conjugada
EP3589314A4 (en) * 2017-02-24 2021-04-21 Merck Sharp & Dohme Corp. INCREASED IMMUNOGENICITY OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE PROTEIN CONJUGATES
EP3634481A4 (en) 2017-06-10 2021-07-21 Inventprise, LLC. MULTIVALENT CONJUGATE VACCINES WITH BIVALENT OR MULTIVALENT CONJUGATE POLYSACCHARIDES THAT CONFIRM ENHANCED IMMUNOGENICITY AND AVIDITY
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
EP3668309A4 (en) * 2017-08-14 2021-06-09 University of Georgia Research Foundation, Inc. PROTEINS WITH PNEUMOCOCCK CAPSULE DEGRADING ACTIVITY AND METHOD OF USING
EP3668541A4 (en) * 2017-08-16 2021-05-26 Merck Sharp & Dohme Corp. FORMULATIONS FOR PNEUMOCOCCAL CONJUGATE VACCINE
CN117018172A (zh) 2017-09-07 2023-11-10 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
WO2019050814A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
BR112020004471A8 (pt) 2017-09-07 2022-11-01 Merck Sharp & Dohme Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
PL3678654T3 (pl) 2017-09-07 2024-12-16 Merck Sharp & Dohme Llc Polisacharydy pneumokokowe i ich zastosowanie w immunogennych koniugatach polisacharyd-białko nośnikowe
EP3691677A4 (en) 2017-10-04 2021-07-07 Pogona, Llc COMPOSITIONS OF SACCHARIDE-POLYPEPTIDE CONJUGATES AND THEIR METHODS OF USE
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
US11116828B2 (en) 2017-12-06 2021-09-14 Merck Sharp & Dohme Corp. Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
AU2019215216B2 (en) * 2018-02-05 2025-04-17 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
SG11202006387QA (en) 2018-02-05 2020-07-29 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2019256218B2 (en) 2018-04-18 2025-10-16 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
CN120661645A (zh) 2018-04-30 2025-09-19 默沙东有限责任公司 生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
EP3787674A4 (en) * 2018-04-30 2022-01-26 Merck Sharp & Dohme Corp. PROCESS FOR THE PRODUCTION OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CAPSULAR PROTEIN CONJUGATES FROM LYOSPHERES
CN112543649A (zh) * 2018-07-04 2021-03-23 Vaxcyte公司 免疫原性缀合物的改进
WO2020009462A1 (ko) * 2018-07-06 2020-01-09 주식회사 유바이오로직스 다가 폐렴구균 다당체-단백질 접합체를 포함하는 면역원성 조성물, 및 이를 포함하는 폐렴구균에 의한 질환 예방 백신
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3852795A4 (en) 2018-09-23 2022-11-23 Biological E Limited PURIFIED CAPSULE POLYSACCHARIDES FROM STREPTOCOCCUS PNEUMONIAE
US11103567B2 (en) 2018-12-06 2021-08-31 Academia Sinica Glycoconjugate vaccines, preparation method and uses thereof
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
GEP20247633B (en) 2018-12-19 2024-06-25 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2020152706A1 (en) * 2019-01-21 2020-07-30 Biological E Limited Multivalent pneumococcal conjugate vaccine compositions
WO2020157772A1 (en) * 2019-01-28 2020-08-06 Biological E Limited Multivalent pneumococcal polysaccharide-protein conjugate vaccine compositions
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
KR102754880B1 (ko) * 2019-05-28 2025-01-13 에스케이바이오사이언스(주) 스트렙토코커스 뉴모니애 혈청형 23f의 면역원성 접합체 제조방법
MX2022001241A (es) * 2019-07-31 2022-04-20 Sanofi Pasteur Inc Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
US20230085173A1 (en) 2020-02-21 2023-03-16 Pfizer Inc. Purification of saccharides
CN115484977B (zh) * 2020-05-01 2025-07-11 神州细胞工程有限公司 一种增强蛋白/肽抗原免疫原性的方法
WO2022035816A1 (en) 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
JP2023546446A (ja) 2020-10-22 2023-11-02 ファイザー・インク 細菌多糖を精製する方法
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3200968A1 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
JP7207495B2 (ja) * 2021-02-05 2023-01-18 株式会社三洋物産 遊技機
EP4346893A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN115721709A (zh) * 2021-08-27 2023-03-03 康希诺生物股份公司 一种肺炎球菌结合疫苗制备方法
AU2023268745A1 (en) 2022-05-11 2024-11-07 Pfizer Inc. Process for producing of vaccine formulations with preservatives
JP2023105293A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機
JP2023105292A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機
JP2023105291A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機
KR20250107930A (ko) * 2022-11-22 2025-07-14 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
CN120513083A (zh) 2022-12-01 2025-08-19 辉瑞大药厂 肺炎链球菌缀合物疫苗制剂
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250169621A (ko) 2023-04-14 2025-12-03 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
US4709017A (en) * 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
ATE245446T1 (de) 1992-02-11 2003-08-15 Jackson H M Found Military Med Dualer träger für immunogene konstrukte
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
CA2135052A1 (en) 1992-05-06 1993-11-11 R. John Collier Diphtheria toxin receptor-binding region
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
PT616034E (pt) 1993-03-05 2005-02-28 Wyeth Corp Plasmideo para a producao de proteina crm e toxina da difteria
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
ATE241384T1 (de) 1995-03-22 2003-06-15 Jackson H M Found Military Med Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
US5714354A (en) * 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
KR19990007777A (ko) * 1995-06-07 1999-01-25 듀크두플레시스 면역성 및 면역자극성 올리고당 조성물 및 이를 제조하고 이용하는 방법
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
JP2001513776A (ja) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＬＰＳ関連障害の処置における非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999051259A2 (en) 1998-04-03 1999-10-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
CN100406060C (zh) 1998-10-16 2008-07-30 史密丝克莱恩比彻姆生物有限公司 一种佐剂组合物
JP4689044B2 (ja) 1998-12-21 2011-05-25 メディミューン，インコーポレーテッド ワクチン用の肺炎連鎖球菌タンパク質と免疫原断片
CA2356836C (en) 1998-12-23 2011-09-13 Shire Biochem Inc. Novel streptococcus antigens
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
NZ513935A (en) 1999-02-17 2004-02-27 Csl Ltd Immunogenic complexes and methods relating thereto
EP1034792A1 (en) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
DE122009000054I1 (de) 1999-03-19 2009-12-31 Glaxosmithkline Biolog Sa Impfstoff gegen bakterielle antigene
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
CO5200838A1 (es) 1999-09-24 2002-09-27 Smithkline Beecham Corp Vacunas
AU765824B2 (en) 1999-09-24 2003-10-02 Smithkline Beecham Biologicals (Sa) Vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
AU2001270381B2 (en) 2000-06-20 2007-05-24 Id Biomedical Corporation Streptococcus antigens
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
EP1456231A2 (en) 2001-12-20 2004-09-15 Shire Biochem Inc. Streptococcus antigens
KR101052996B1 (ko) 2003-03-13 2011-07-29 글락소스미스클라인 바이오로지칼즈 에스.에이. 박테리아 세포용해소에 대한 정제 공정
CA2519511A1 (en) * 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
JP2008506789A (ja) 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
AU2005333126A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing innate immune responses
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
CN104815327A (zh) * 2005-04-08 2015-08-05 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
HUE050049T2 (hu) 2005-04-08 2020-11-30 Wyeth Llc Szennyezõanyagok elválasztása streptococcus pneumoniae poliszacharidtól PH manipulációjával
UA95237C2 (uk) * 2005-06-27 2011-07-25 Ґлаксосмітклайн Байолоджікалз С.А. Імуногенна композиція
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
PT1973564T (pt) * 2005-12-22 2017-01-24 Glaxosmithkline Biologicals Sa Vacina compreendendo conjugados polissacarídicos capsulares de streptococcus pneumoniae
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2008045852A2 (en) 2006-10-10 2008-04-17 Wyeth Purification of streptococcus pneumoniae type 3 polysaccharides
UA99278C2 (ru) 2007-03-23 2012-08-10 УАЙЕТ ЭлЭлСи Способ получения существенно очищенных капсульных полисахаридов из лизата клеток streptococcus pneumoniae
CN101754773A (zh) * 2007-06-20 2010-06-23 巴克斯特国际有限公司 用于缀合疫苗的经过修饰的多糖
AU2008267208B2 (en) * 2007-06-26 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
AU2010227221B2 (en) * 2009-03-24 2015-01-22 Novartis Ag Combinations including pneumococcal serotype 14 saccharide
RU2536248C2 (ru) 2009-04-30 2014-12-20 Коули Фармасьютикал Груп, Инк. Пневмококковая вакцина и ее применения
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
WO2011145108A2 (en) * 2010-05-15 2011-11-24 Serum Institute Of India Ltd. Purification of capsular polysaccharides
BR112013012626A2 (pt) * 2010-12-10 2016-07-19 Merck Sharp & Dohme formulação, composição imunogênica, e, seringa pré-carregada
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
PT2885007T (pt) * 2012-08-16 2018-12-10 Pfizer Processos e composições de glicoconjugação
HUE060718T2 (hu) 2012-12-20 2023-04-28 Pfizer Glikokonjugációs eljárás
ITMI20130142A1 (it) * 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
CN103495161B (zh) 2013-10-08 2019-06-18 江苏康泰生物医学技术有限公司 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法
EP3607966A1 (en) 2014-01-21 2020-02-12 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Also Published As

Publication number Publication date
TW202112392A (zh) 2021-04-01
MX379051B (es) 2025-03-11
CA3170344A1 (en) 2015-07-30
TWI715285B (zh) 2021-01-01
CN119303072A (zh) 2025-01-14
TWI748810B (zh) 2021-12-01
RU2016129991A3 (ar) 2018-03-01
MX2021000522A (es) 2021-06-08
CN106102770B (zh) 2022-03-22
NZ755770A (en) 2023-06-30
EP3096785A2 (en) 2016-11-30
TW202003024A (zh) 2020-01-16
FR22C1028I1 (fr) 2022-09-09
JP2018135374A (ja) 2018-08-30
IL282215A (en) 2021-05-31
IL282215B2 (en) 2023-02-01
SG11201604728XA (en) 2016-08-30
HUE051728T2 (hu) 2021-03-29
NZ721943A (en) 2022-07-01
NZ755769A (en) 2023-06-30
HUS2200029I1 (hu) 2022-07-28
IL312327A (en) 2024-06-01
AR130929A2 (es) 2025-01-29
EP3616716A3 (en) 2020-05-06
LUC00268I2 (ar) 2025-04-25
TW201828978A (zh) 2018-08-16
KR20230021167A (ko) 2023-02-13
AU2025237966A1 (en) 2025-10-16
IL296681B1 (en) 2024-05-01
MX2021000520A (es) 2021-06-08
JP6335326B2 (ja) 2018-05-30
ZA201603925B (en) 2017-09-27
AU2017268651B2 (en) 2019-08-01
IL282215B (en) 2022-10-01
IL283058B2 (en) 2023-02-01
PH12021550318A1 (en) 2021-10-04
DK3096785T3 (da) 2020-09-21
FR22C1028I2 (fr) 2025-01-03
IL246853B (en) 2021-04-29
AU2021206895A1 (en) 2021-08-12
SG10201803187VA (en) 2018-05-30
CA2937186C (en) 2022-11-01
KR20240146095A (ko) 2024-10-07
CN110859957B (zh) 2024-04-12
CN106102770A (zh) 2016-11-09
AU2017268651A1 (en) 2017-12-21
BR112016015525A2 (pt) 2017-10-24
HUS2200035I1 (hu) 2022-08-28
LUC00274I2 (ar) 2025-05-12
MX2021000523A (es) 2021-06-23
AR130928A2 (es) 2025-01-29
EP3616716A2 (en) 2020-03-04
PL3096785T3 (pl) 2021-03-08
RU2687460C2 (ru) 2019-05-13
CN110859957A (zh) 2020-03-06
JP7059095B2 (ja) 2022-04-25
JP2020164550A (ja) 2020-10-08
PH12016501243B1 (en) 2021-10-29
CN114887048A (zh) 2022-08-12
RU2016129991A (ru) 2018-03-01
ES2820824T3 (es) 2021-04-22
RU2019112411A3 (ar) 2021-06-24
CA2937186A1 (en) 2015-07-30
NZ760783A (en) 2023-07-28
IL312327B1 (en) 2025-10-01
AU2021206895B2 (en) 2024-02-22
SA516371506B1 (ar) 2021-06-01
AR099445A1 (es) 2016-07-27
IL246853A0 (en) 2016-08-31
AU2015208821A1 (en) 2016-07-07
TWI679987B (zh) 2019-12-21
US9492559B2 (en) 2016-11-15
EP3607966A1 (en) 2020-02-12
NO2022035I1 (no) 2022-08-04
TW201531299A (zh) 2015-08-16
EP3096785B1 (en) 2020-09-09
KR20200108496A (ko) 2020-09-18
TWI682778B (zh) 2020-01-21
AU2015208821B2 (en) 2017-11-02
NO2022021I1 (no) 2022-06-09
SI3096785T1 (sl) 2020-12-31
PT3096785T (pt) 2020-10-13
RU2019112411A (ru) 2019-05-31
PE20212335A1 (es) 2021-12-16
AU2021206895C1 (en) 2024-07-25
JP7579900B2 (ja) 2024-11-08
IL270090B (en) 2021-05-31
AU2019204623A1 (en) 2019-07-18
CN110787290B (zh) 2024-06-04
PE20161095A1 (es) 2016-10-26
CN114848805A (zh) 2022-08-05
KR20220080201A (ko) 2022-06-14
IL312327B2 (en) 2026-02-01
WO2015110941A3 (en) 2015-11-26
CN110787290A (zh) 2020-02-14
IL296681A (en) 2022-11-01
JP7227943B2 (ja) 2023-02-22
AU2024201996A1 (en) 2024-05-16
US20150202309A1 (en) 2015-07-23
FR22C1040I1 (fr) 2022-09-09
IL283058B (en) 2022-10-01
AU2019204623B2 (en) 2021-04-29
JP2025020213A (ja) 2025-02-12
CA3170344C (en) 2023-08-29
JP2017509656A (ja) 2017-04-06
KR102157200B1 (ko) 2020-09-21
PH12016501243A1 (en) 2016-08-15
MX2016009470A (es) 2017-01-18
CN114887048B (zh) 2025-09-05
NZ759686A (en) 2023-07-28
CA3206112A1 (en) 2015-07-30
KR20160098507A (ko) 2016-08-18
JP2023065429A (ja) 2023-05-12
IL283058A (en) 2021-06-30
JP2025020211A (ja) 2025-02-12
IL296681B2 (en) 2024-09-01
WO2015110941A2 (en) 2015-07-30
RU2771293C2 (ru) 2022-04-29

Similar Documents

Publication Publication Date Title
PH12021550318A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PH12018500037A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
MX392525B (es) Composiciones inmunogenicas para su uso en vacunas neumococicas
BR112018007812A2 (pt) polissacarídeo capsular, processo para preparar um polissacarídeo capsular e para fabricar uma vacina, composição imunogênica, vacina, métodos para tratamento ou prevenção de uma infecção, para imunizar um hospedeiro humano e para induzir uma resposta imune, e, uso de uma composição imunogênica.
MX2016000099A (es) Vacunas sinteticas contra streptococcus pneumoniae tipo 1.
WO2016198170A8 (en) Vaccines against streptococcus pneumoniae serotype 5
PH12019500377B1 (en) Composition comprising multivalent capsular polysaccharide-transport protein and use thereof
PH12018501205A1 (en) Synthetic vaccines against streptococcus pneumoniae serotype 2
CA3010537A1 (en) Vaccine strains of brachyspira hyodysenteriae